Following the announcement of Valeant Pharmaceuticals International Inc.’s plans to acquire Raleigh, North Carolina-based Salix Pharmaceuticals Ltd. for $10.1 billion late last month, a rival $11.2 billion bid for the target emerged Wednesday from Endo International plc.
Skadden, Arps, Slate, Meagher & Flom, a firm familiar with twisted pharmaceutical takeover battles, is serving as lead counsel to Endo on its offer for Salix. The firm is also handling finance and antitrust aspects of Valeant’s bid for the company. Skadden declined to comment on its work representing both potential Salix acquirers.
